Article Text

other Versions

PDF
Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience
  1. Laura C Coates (lauraccoates{at}gmail.com)
  1. University of Leeds, United Kingdom
    1. Lorna S Cawkwell (lornacawkwell{at}hotmail.co.uk)
    1. University of Leeds, United Kingdom
      1. Nora W F Ng (norang{at}doctors.org.uk)
      1. University of Leeds, United Kingdom
        1. Alexander N Bennett (alexandernbennett{at}btinternet.com)
        1. University of Leeds, United Kingdom
          1. Domini J Bryer (domini.bryer{at}leedsth.nhs.uk)
          1. University of Leeds, United Kingdom
            1. Alexander D Fraser (drsandyfraser{at}aol.com)
            1. University of Leeds, United Kingdom
              1. Paul Emery (p.emery{at}leeds.ac.uk)
              1. Dept of Rheumatology, United Kingdom
                1. Helena Marzo-Ortega (medhmo{at}leeds.ac.uk)
                1. University of Leeds, United Kingdom

                  Abstract

                  Objective: To investigate the response to biologic drugs in psoriatic arthritis and to quantify non-response and outcome from switching agents.

                  Methods: 60 patients (33M:27F, mean age 46 years, median disease duration 16 years) prescribed biologic drugs for psoriatic arthritis between 2001 and 2006 were studied. Response was evaluated using joint counts, CRP levels and DAS28 scores.

                  Results: The mean percentage improvements seen were 56% in tender joint count, 70% in swollen joint count, 64% in CRP level and 36% in the overall DAS score. Improvements were sustained beyond 24 months with no loss of effect. Side-effects leading to cessation or switching of first-line therapy were only seen in 5% of patients and non-response occurred in 20% long term. Overall, 90% of patients achieved a significant response, using switching in 20% of cases. Outcomes were similar regardless of drug used, duration of disease and sub-type of arthritis.

                  Conclusion: Treatment of active PsA with anti-TNF agents leads to a sustained response over three years with most patients tolerating these drugs well. The rate of non-response is low with the majority of patients responding to second and third line therapies.

                  • TNF blockers
                  • biologics
                  • non-response
                  • psoriatic arthritis
                  • switching

                  Statistics from Altmetric.com

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.